ライフサイエンスコーパス: vaccine immunogenicity

1 le of macrophages as mediators of RABV-based vaccine immunogenicity.

2 abies vaccine was shown to result in reduced vaccine immunogenicity.

3 s is likely to be an important attribute for vaccine immunogenicity.

4 these mutations to virulence attenuation and vaccine immunogenicity.

5 to optimize this regimen to further augment vaccine immunogenicity.

6 g specific antibody sequences as measures of vaccine immunogenicity.

7 f evaluating the naive repertoire to predict vaccine immunogenicity.

8 echanisms that may be manipulated to enhance vaccine immunogenicity.

9 mplified vaccination logistics and increased vaccine immunogenicity.

10 er antibiotics would improve oral poliovirus vaccine immunogenicity.

11 to boost immune function to enhance anti-HIV vaccine immunogenicity.

12 ted only minimal suppressive effects on rAd5 vaccine immunogenicity.

13 in the evaluation of disease pathogenesis or vaccine immunogenicity.

14 observed, but were insufficient to suppress vaccine immunogenicity.

15 n is a critical rate-limiting factor for DNA vaccine immunogenicity.

16 he MHC class II cytoplasmic domain abrogates vaccine immunogenicity.

17 s additional studies designed to enhance DNA vaccine immunogenicity.

18 CpGs therefore can efficiently improve vaccines' immunogenicity.

19 transient overexpression of BAFF to enhance vaccine immunogenicity, a replication-deficient adenovir

20 being focused on adjuvants that can broaden vaccine immunogenicity against emerging viruses and maxi

21 D4(+) T cells in blood is an early marker of vaccine immunogenicity and an important immune parameter

22 Vaccine immunogenicity and antitumor potency were enhanc

23 in rhesus macaques, commonly used to assess vaccine immunogenicity and efficacy.

24 the lack of human in vitro models to assess vaccine immunogenicity and efficacy.

25 orage of rPA vaccines would adversely affect vaccine immunogenicity and therefore the storage life of

26 e and host genetics may significantly impact vaccine immunogenicity and/or efficacy, whether LPS is a

27 r understanding of the relationships between vaccine, immunogenicity and protection from disease woul

28 severity of the first confirmed recurrence, vaccine immunogenicity, and rates of local and systemic

29 Adjuvants such as AS03 improve vaccine immunogenicity, but this mechanism is poorly und

30 n represents a promising strategy to augment vaccine immunogenicity by targeting Ag to mannose recept

31 To evaluate vaccine immunogenicity, children who had received the re

32 ministration of zoster vaccine could enhance vaccine immunogenicity compared with conventional needle

33 during a randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004588).

34 Quadrivalent HPV vaccine immunogenicity delivered on 3 alternative dosing

35 These results reinforce the notion that vaccine immunogenicity does not predict control of AIDS

36 posal, and offer the possibility of improved vaccine immunogenicity, dose sparing and thermostability

37 ly used as the gold standard for determining vaccine immunogenicity, even though their role in cleara

38 sociated with reduced morbidity and enhanced vaccine immunogenicity for inducing antibodies and T cel

39 ore, an insight is provided to the impact on vaccine immunogenicity from altering vaccination methods

40 The potential effect of fH binding on vaccine immunogenicity had not been assessed in experime

41 DNA vaccine immunogenicity has been limited by inefficient d

42 For outer membrane vesicle (OMV) vaccines, immunogenicity has primarily been determined b

43 ctors associated with pneumococcal conjugate vaccine immunogenicity have not been explored.

44 y, we find that DCs are essential for MHC II vaccine immunogenicity; however, they mediate their effe

45 ses, making this a new possible indicator of vaccine immunogenicity in children.

46 should be evaluated for improving rotavirus vaccine immunogenicity in high burden countries.

47 xplored as a potential method to enhance DNA vaccine immunogenicity in humans.

48 nant protein boost would impact HIV-specific vaccine immunogenicity in rhesus macaques (RhM).

49 odominant regions should improve the overall vaccine immunogenicity in the local population and minim

50 e development of novel adjuvants to increase vaccine immunogenicity is an important goal that seeks t

51 Influenza vaccine immunogenicity is suboptimal in immunocompromise

52 However, standard assays of experimental HIV vaccine immunogenicity may not correlate with antiviral

53 tigens has the potential to adversely affect vaccine immunogenicity over time.

54 Existing methods to measure influenza vaccine immunogenicity prohibit detailed analysis of epi

55 The treatment did not augment vaccine immunogenicity; rather, it dramatically increase

56 We assessed vaccine immunogenicity, safety, and three primary outcom

57 NA vaccine-induced pyroptotic cell death and vaccine immunogenicity that is instrumental in shaping t

58 n mice and 50-valent in rhesus macaques, HRV vaccine immunogenicity was related to sufficient quantit

59 of new-generation anthrax vaccines--affects vaccine immunogenicity, we created a "genetically deamid

60 To improve vaccine immunogenicity, we incorporated CD40 ligand (CD4

61 nd effective cross-species method to improve vaccine immunogenicity with potentially broad applicabil